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Abstract
Background: Recent studies have suggested that essential tremor (ET) is a more complex and heterogeneous clinical entity
than initially thought. In the present study, we assessed the pattern of cortical thickness and diffusion tensor white matter
(WM) changes in patients with ET according to the response to propranolol to explore the pathogenesis underlying the
clinical heterogeneity of ET.
Methods: A total of 32 patients with drug naive ET were recruited prospectively from the Movement Disorders outpatient
clinic. The patients were divided into a propranolol-responder group (n= 18) and a non-responder group (n= 14). We
analyzed the pattern of cortical thickness and diffusion tensor WM changes between these two groups and performed
correlation analysis between imaging and clinical parameters.
Results: There were no significant differences in demographic characteristics, general cognition, or results of detailed
neuropsychological tests between the groups. The non-responder group showed more severe cortical atrophy in the left
orbitofrontal cortex and right temporal cortex relative to responders. However, the responders exhibited significantly lower
fractional anisotropy values in the bilateral frontal, corpus callosal, and right parietotemporal WM compared with the non-
responder group. There were no significant clusters where the cortical thickness or WM alterations were significantly
correlated with initial tremor severity or disease duration.
Conclusions: The present data suggest that patients with ET have heterogeneous cortical thinning and WM alteration with
respect to responsiveness to propranolol, suggesting that propranolol responsiveness may be a predictive factor to
determine ET subtypes in terms of neuroanatomical heterogeneity.
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Introduction
Essential tremor (ET) is one of the most common movement
disorders and has been widely regarded as a monosymptomatic
condition, characterized by kinetic arm tremor [1,2]. However, as
our understanding of ET is advancing, the concept of ET as a
more complex and heterogeneous clinical entity has been rapidly
gaining acceptance, although evidence suggesting that ET is likely
a neurodegenerative disorder is still inconclusive. Several clinical
series indicated that patients with ET had additional neurological
signs including cognitive impairment, cerebellar disturbances, and
olfactory deficits [3–6]. Additionally, the neuropathological studies
indicated that the majority of ET cases have changes in the
cerebellum, whereas some had Lewy bodies (LB) or neuronal
depletion in the brainstem, mainly in the locus coeruleus (LC) [7–
9].
The pathophysiology of ET also remains unclear. One possible
explanation is that the abnormal intrinsic oscillations influence the
cerebello–thalamo–cortical loop. Several neuroimaging studies
using positron emission tomography (PET), voxel-based mor-
phometry, and diffusion tensor imaging (DTI) in patients with ET
supported the disintegration of this loop [10–18]. However, no
neuroimaging studies have evaluated the neuroanatomical sub-
strates for complex clinical characteristics of ET. Only recently
have postmortem studies attempted to correlate the heterogeneous
clinicopathological findings, and these showed that some clinical
characteristics tended to differ between ET patients with and
without LB pathologies [7,8].
We hypothesized that the variable responsiveness to propran-
olol, which is one of the most widely used and efficacious anti-
tremor drugs, may reflect underlying structural or functional
changes in individuals with ET. Indeed, about 30% of patients
with ET do not respond to propranolol, and some cases show
tolerance to the drug effect with chronic treatment [19].
Therefore, we assessed the pattern of cortical thickness and
diffusion tensor white matter (WM) changes in patients with ET
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according to the response to propranolol to explore the
pathogenesis underlying the clinical heterogeneity of ET.
Patients and Methods
Subjects
The study population consisted of 32 patients with drug naive
ET recruited from the Movement Disorders outpatient clinic at
Severance Hospital, Seoul, Korea, between March and October
2012. ET was diagnosed according to the criteria of the
Movement Disorder Society on Tremor [20]. Patients had no
history of exposure to ET medications, such as beta-blockers and
primidone. Each subject underwent brain magnetic resonance
imaging (MRI), the cross-cultural smell identification test (CCSIT)
[21], and a neuropsychological test battery. The severity of ET
was assessed with the Fahn–Tolosa–Marin tremor rating scale
(TRS) [22].
Exclusion criteria included the presence of medical comorbid-
ities interfering with the use of beta-blockers (e.g., asthma,
atrioventricular block), other neurological signs (e.g., dystonia,
parkinsonian features), a history of exposure to tremorgenic drugs
(e.g., gastrointestinal drugs, neuroleptics), and evidence of focal
brain lesions, multiple lacunes, or diffuse areas of WM
hyperintensity on brain MRI.
This study was approved by the Yonsei University Severance
Hospital institutional review board. Written informed consent was
obtained from all subjects who participated in this study.
Assessment of response to propranolol
Each subject was initially treated with the beta-blocker,
propranolol, with escalation of dose from 40 mg/day to 80 mg/
day after 2 weeks, which was widely established as a standard care
for ET. Movement disorders specialists (Y.H.S. and P.H.L. who
involved in the current study) prescribed propranolol in the
outpatient clinic. The severity of tremor was assessed twice with
the Fahn–Tolosa–Marin TRS for all patients, i.e., at baseline on
the first visit and on the second visit after 8 weeks of medication.
The Fahn–Tolosa–Marin TRS consisted of three parts: Part A
(amplitude of tremor in different body parts); Part B (tremor in
writing, drawing, and pouring); and Part C (functional disabilities
in daily living). Each item was scored from 0 (none) to 4 (severe),
and the total possible score was 156. The improvement of total
TRS scores after 8 weeks (response rate) was calculated. The
patients were then divided into two groups according to the
response to propranolol: responders, over 25% improvement in
total TRS scores; non-responders, below 25% improvement in
total TRS scores [23].
Neuropsychological assessment
All subjects were administered the Seoul Neuropsychological
Screening Battery (SNSB) [24], which is a detailed Korean
language neuropsychological test battery consisting of five
cognitive domains: attention (forward/backward digit span and
letter cancellation); language and related functions (Korean
version of the Boston Naming Test [K-BNT], calculation, and
praxis); visuospatial function (Rey Complex Figure Test [RCFT]);
memory (three-word registration/recall and Seoul Verbal Learn-
ing Test [SVLT] for verbal memory; immediate recall/delayed
recall/recognition using RCFT for visual memory); and frontal/
executive function (contrasting program, go/no-go test, Controlled
Oral Word Association Test [COWAT], and Stroop test). The
scores for each cognitive domain were determined as abnormal
when they were below the 16th percentile of the age-, sex-, and
education-specific norms of 447 healthy control subjects.
MRI acquisition
All MRI scans of ET patients were acquired using a Philips 3.0
T scanner (Philips Intera; Philips Medical System, Best, The
Netherlands) with a SENSE head coil (SENSE factor = 2). The
high-resolution T1-weighted MRI data were obtained axially from
all subjects using a 3D T1-TFE sequence with the following
parameters: 2246224 axial acquisition matrix; 2566256 recon-
structed matrix with 170 slices; field of view, 220 mm; voxel size,
0.85960.85961 mm3; echo time, 4.6 ms; repetition time, 9.8 ms;
flip angle, 8u. The diffusion-weighted MRI data were obtained
from 30 subjects using a single-shot echo-planar acquisition with
the following parameters: 45 non-collinear, non-coplanar diffu-
sion-encoded gradient directions; 1286128 acquisition matrix
with 70 slices; field of view, 220 mm; voxel size,
1.7561.7562 mm3; echo time, 70 ms; repetition time, 7.663 s;
flip angle, 90u; b-factor, 600 s/mm2.
Analysis of cortical thickness
The following steps were applied to high-resolution T1-
weighted MRI data, which have been described in detail elsewhere
[25–29]. A fully 3D technique for inhomogeneity correction
removed a serious obstacle for automated segmentation of MRI,
which slowly varied the change in signal intensity over the image
caused by magnetic field inhomogeneity [26]. To account for
interindividual differences in absolute brain size, each brain was
separately transformed to a standardized stereotactic space and
resampled on a 1-mm3 voxel grid. This procedure was performed
with automatic registration software using a 3D cross-correlation
approach to match the single MRI volume, with the intensity
average of 305 MRI brain volumes previously aligned in a
standardized stereotactic space [25]. An artificial neural network
classifier was applied to identify gray matter (GM), WM, and
cerebrospinal fluid (CSF) [28]. The cortical surface was automat-
ically extracted from each MR volume using the Constrained
Laplacian-based Automated Segmentation with Proximities
(CLASP) algorithm. Cortical thickness was calculated as the
Euclidean distance between the corresponding vertices of the inner
and outer cortical surfaces [30].
We analyzed the global difference and corrected t-statistical
maps of cortical thickness between the groups, adjusting for age,
sex, years of education, disease duration, and intracranial volume
as covariates. Statistical analyses were performed using SurfStat
toolbox (http://www.math.mcgill.ca/keith/surfstat/), for Matlab
(R2008b; MathWorks, Natick, MA). The results for the between-
group differences in cortical thickness were considered significant
at random-field theory (RFT)-corrected P,0.05 [31].
DTI processing
DTI data were preprocessed using the Functional Magnetic
Resonance Imaging of the Brain (FMRIB) Software Library (FSL)
program (http://www.fmrib.ox.ac.uk/fsl/). Motion artifacts and
eddy current distortions were corrected by normalization of each
directional volume to the non-diffusion-weighted volume (b0)
using the FMRIB Linear Image Registration Tool (FLIRT) with 6
degrees of freedom. After correction of motion artifacts and eddy
current distortions, the diffusion tensor was calculated using a
simple least-squares fit of the tensor model. Then, the fractional
anisotropy (FA) and mean diffusivity (MD) were determined for
each voxel using standard methods of the DTIFIT program in
FSL.
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Tract-based spatial statistics (TBSS) analysis
The FA and MD maps of DTI preprocessing results were used
in TBSS analysis. All FA images were aligned to the standard
FMRIB58 FA template provided by the FSL program using a
nonlinear registration algorithm implemented in the TBSS
package. The FA images were then averaged to create a
skeletonized mean FA image. Each subject’s aligned FA images
were projected onto this skeleton by filling the skeleton with the
highest FA values from the nearest relevant center of fiber tracts
[32]. A threshold FA value of 0.2 was chosen to exclude voxels of
adjacent GM or CSF. The MD images were also processed using
identical methods to the FA data by applying the nonlinear
registration algorithm and projecting them onto the skeleton.
To compare the values for the responder and non-responder
groups, voxel-wise statistical analysis of individual skeleton images
was performed using a nonparametric permutation test. Age, sex,
years of education, and disease duration were included as
covariates in the analysis of covariance (ANCOVA). The null
distribution was built up over 5000 permutations. For control over
the multiple comparison correction, we used the threshold-free
cluster enhancement (TFCE) approach with the 2D parameter
settings [33]. The results for FA and MD were considered
significant for familywise error (FWE)-corrected P,0.05. The FA
is an index of directional selectivity of water diffusion, and the MD
is the average diffusivity of three dimensions, where decreased FA
and increased MD are indicative of WM disintegration.
Correlation analysis
Multiple regression analysis was performed to determine the
correlations between cortical thickness and initial tremor severity
assessed by TRS or disease duration, adjusting for age, sex, years
of education, and intracranial volume as covariates. The result for
cortical thickness was considered significant at RFT-corrected
P,0.05. Analysis of correlations between FA values and total TRS
score or disease duration was also performed, adjusting for age,
sex, and years of education. The results for FA and MD were
considered significant at FWE-corrected P,0.05.
Statistical analysis
To compare the baseline demographic characteristics of the two
groups, the Mann–Whitney U-test and Fisher’s exact test were
used for continuous and categorical variables, respectively.
Multiple linear regression analysis was used to compare the
subscores of the detailed neuropsychological test, adjusting for age,
sex, and years of education. Statistical analyses were performed
using SPSS version 18.0 (SPSS, Inc., Chicago, IL, USA), and two-
tailed P,0.05 was considered significant.
Results
Demographic characteristics
Table 1 shows the baseline demographic characteristics of the
patients with ET (18 responders and 14 non-responders). There
Table 1. Baseline demographic characteristics.
Responder (n =18) Nonresponder (n=14) P
Age 62.4 (8.6) 63.2 (10.5) 0.821
Female, No. (%) 13 (72.2) 8 (57.1) 0.465
Education (years) 9.0 (0–18) 12.0 (3–18) 0.924
Age at onset 44.1 (16.5) 46.6 (16.1) 0.662
Duration (years) 15.0 (4–50) 11.5 (5–40) 0.985
K-MMSE 28.0 (17–30) 29.0 (19–30) 0.668
CDR 0.25 (0–1) 0.25 (0–1) NS
CDR (SOB) 0.25 (0–3) 0.25 (0–3) 0.790
CCSIT 10.0 (5–12) 9.0 (4–11) 0.255
Family history, No. (%) 16 (88.9) 9 (64.3) 0.195
Limb tremor, No. (%) 18 (100) 14 (100) NS
Head tremor, No. (%) 11 (61.1) 8 (57.1) 0.821
Before medication
TRS A 11.5 (6–23) 12.5 (5–42) 0.819
TRS B 14.0 (2–26) 12.0 (4–36) 0.924
TRS C 7.5 (2–19) 8.0 (2–31) 0.351
TRS total 31.5 (12–67) 36.5 (12–109) 0.582
After medication
TRS A 7.0 (3–17) 12.5 (5–42) 0.030
TRS B 8.0 (1–21) 12.5 (4–36) 0.031
TRS C 4.0 (0–14) 8.0 (2–31) 0.027
TRS total 21.0 (5–50) 36.5 (12–109) 0.013
Response rate
TRS total 33.85 (25.0–58.7) 0.00 (22.7–8.6) ,0.001
The values are expressed as median (minimum -maximum), mean (SD), or number (percentage). Abbreviations: K-MMSE, Korean version of Mini-Mental State
Examination; CDR, Clinical Dementia Rating; SOB, Sum of Boxes; CCSIT, Cross cultural smell identification test; TRS, tremor rating scale; NS, not significant.
doi:10.1371/journal.pone.0084054.t001
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were no significant differences in age, sex, years of education, or
general cognitive deficits as measured by the Korean version of the
Mini-Mental State Examination (K-MMSE) [34] or Clinical
Dementia Rating (CDR) [35] between the two groups. There
were also no significant differences in duration of tremor, olfactory
function measured by the CCSIT, or the presence of family history
of ET between the two groups. Additionally, the initial tremor
severity assessed by the Fahn–Tolosa–Marin TRS was not
significantly different between the groups. A detailed neuropsy-
chological test battery, the SNSB, also showed no significant
differences in each cognitive domain (Table S1). Subanalyses were
performed for 30 of 32 patients with ET (16 responders and 14
non-responders) for whom DTI data were available. There were
no significant differences in the baseline demographic character-
istics or neuropsychological test results between responders and
non-responders (data not shown).
Analysis of cortical thickness
The mean difference maps of cortical thickness between the two
groups (18 responders and 14 non-responders) are shown in
Figure 1A. The color scale bar at the bottom represents the
between-group differences in cortical thickness. In this color scale,
blue and red indicates less and greater cortical thickness,
respectively, in the non-responder group compared with the
responder group. The non-responder group tended to show less
cortical thickness in the left orbitofrontal cortex (OFC) and right
superolateral temporal lobe. Figure 1B shows the corrected t-
statistical maps of cortical thickness. Significant differences were
observed in the left orbital gyrus and right middle temporal gyrus,
where the non-responders exhibited less cortical thickness than did
the responders (RFT-corrected P,0.05). No areas were found in
which the non-responders had greater cortical thickness compared
with the responders.
TBSS analysis
The non-responders exhibited significantly higher FA values in
the bilateral frontal, corpus callosal (genu), and right parietotem-
poral WM than the responders did (FWE-corrected P,0.05;
Figure 2). The non-responder group did not have areas with
significantly reduced FA values (i.e., more severe structural WM
change) compared with the responder group. There were no
significant MD differences between the groups.
Figure 1. Analysis of cortical thickness in comparing responders versus non-responders. (A) Difference maps of cortical thickness
between two groups. The color scale bar shows the difference in mean cortical thickness between the two groups, with blue and red indicating less
and greater cortical thickness in non-responders, respectively. (B) Corrected t-statistical maps of cortical thickness. The non-responders had
significantly less cortical thickness in the left orbital gyrus and right middle temporal gyrus compared with the responders (RFT-corrected P,0.05).
doi:10.1371/journal.pone.0084054.g001
Figure 2. TBSS analysis of fractional anisotropy (FA) in
comparison of responder and non-responder groups. Higher
FA values of the non-responders compared with the responders were
found in the bilateral frontal, corpus callosal (genu), and right
parietotemporal WM (FWE-corrected P,0.05).
doi:10.1371/journal.pone.0084054.g002
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Correlation analysis
No significant clusters where the cortical thickness was
significantly correlated with initial tremor severity assessed by
TRS were observed. Additionally, the FA values were not
significantly correlated with the severity of tremor. Furthermore,
the disease duration was not significantly correlated with either
cortical thinning or FA value.
Discussion
The present study demonstrated that patients with ET who had
no response to propranolol exhibited reduced cortical thickness in
the left orbitofrontal and middle temporal areas compared with
those who responded to this agent. Our study also showed that the
responders had greater disintegration of WM in the regions
corresponding to the fibers of the cerebello–thalamo–cortical loop,
despite the absence of significant differences in age, sex, disease
duration, and cognitive level. These data suggest that patients with
ET have heterogeneous cortical thinning and WM alteration with
respect to responsiveness to propranolol.
Cortical thinning measurement and DTI tractography have
been frequently used to investigate the patterns of anatomical
connectivity in the human brain [36,37]. These approaches have
been widely applied in several neurological disorders to under-
stand the neural correlates of each disorder [38–40]. Thus,
heterogeneous cortical thinning and WM alteration of ET patients
may reflect the different anatomical connectivity and subsequently
lead to distinct clinical features.
The mechanism by which beta-blockers alleviate symptoms in
patients with ET is still unclear. Some studies have suggested that
beta-blockers may act on peripheral beta-adrenoreceptors in the
muscle fibers or spindles [41–43]. Other conflicting findings
supported a possible role of beta-blockers via a central action,
based on the different pharmacokinetics and effects on ET of
various beta-blockers [44,45]. However, the central neuroana-
tomical substrate that is responsible for the pharmacological
actions of beta-blockers in ET has not been established. Among
several possible structures, the LC has been suggested as a strong
candidate [46,47], as it is the primary source of noradrenergic
innervations and expresses beta-adrenoreceptors [48]. Recently,
Baker et al. reported anti-tremor effects of beta-blockers through a
central site of action [47]. Based on changes in corticomuscular
coherence patterns, they speculated that beta-blockers act
centrally through modulation of Renshaw cells, mediated
indirectly via inputs from neurons expressing beta-adrenorecep-
tors, such as those in the LC. Furthermore, several series have
reported a possible role of the LC in the pathogenesis of ET.
Animal studies using a harmaline-induced tremor model showed
that a lesion of the LC augmented the tremor [49,50]. Recent
neuropathological studies of patients with ET revealed that some
cases had abundant LB or neuronal loss in the LC [7,9]. The
Purkinje cells in the cerebellum are known to be innervated by
noradrenergic terminals arising from the LC with an inhibitory
influence [51,52], and this coerulo-cerebellar pathway extends
projections to the subcortical cerebellar nuclei, thalamus, and
cerebral cortex [53–55]. Therefore, any lesion in this pathway,
including the LC, may lead to alteration in the function of the
Purkinje cells and disintegration of the cerebello–thalamo–cortical
loop.
In addition to these possible roles of the LC in ET, the LC also
projects its noradrenergic innervations to all regions of the brain,
including the neocortex, hippocampus, thalamus, subthalamic
nucleus, and substantia nigra, and plays roles in several important
functions, such as arousal, adaptive gain, and optimal performance
[56]. To regulate these functions of the LC, major cortical
glutamatergic afferents to LC are known to arise from the
orbitofrontal and anterior cingulate cortices [57]. Accordingly, it is
possible that this connection between the OFC and LC could have
an indirect influence on the pathogenesis of tremor. In the present
study, the cortical thinning observed in the OFC of non-
responders may have affected the projections to the LC, leading
to subsequent alterations of LC functions, which may contribute to
the pathogenesis of ET in the non-responder group. More
importantly, this alteration in the OFC–LC pathway may lead
to changes in a central action of propranolol mediated by the LC,
which may explain OFC thinning in non-responders. Although
the clinical significance of LC in ET remains uncertain, a few
clinicopathological correlation studies indicated that ET patients
with LB in the LC tended to have older age of onset, less frequent
family history of ET, lower incidence of gait difficulty, and greater
likelihood of taking medications for ET than those without LB
[7,8]. Taken together, these results suggest that dysfunction in the
LC-related structures may contribute to heterogeneous clinical
phenotypes with respect to beta-blocker responsiveness (Figure 3A).
Interestingly, our results of TBSS analysis showed that the
responders exhibited more severe disintegration of WM, mainly in
the frontal lobe, with relatively preserved cortical thickness in the
OFC. This anatomical discrepancy between WM pathology and
GM atrophy suggests that the structural changes of WM in the
responders would not result from secondary degeneration adjacent
to GM abnormalities. Rather, this reflects primary damage in the
fibers corresponding with the cerebello–thalamo–cortical loop,
which is known to be an important pathway in the pathogenesis of
ET. Consistent with these observations, our previous neuroimag-
ing study in different ET patients indicated that patients with ET
exhibited reduced FA value of the WM in a similar area in this
study compared with healthy controls [14]. Therefore, the present
study suggested that responders may have a distinct WM
pathology, primarily involving the cerebello–thalamo–cortical
loop, with preserved structural integrity around the LC compared
with non-responders (Figure 3B).
Previous DTI studies in ET patients have reported inconsistent
results in regard to whether the clinical features correlate with
WM changes [15,16,18]. In our study, correlation analysis
indicated that the parameters of tremor severity and disease
duration were not significantly correlated with regional cortical
thinning or WM alterations. These observations further support
the role of propranolol responsiveness as an important factor for
ET heterogeneity. In addition, with regard to patterns of clinical
parameters in drug responsiveness, there were no significant
differences in demographic characteristics or cognitive perfor-
mance between the two groups in the present study. However, the
responder group exhibited more severe WM alterations in the
fronto-subcortical circuits that are responsible for cognitive
dysfunctions in ET [3,58]. Thus, a longitudinal study focusing
on changes in cognitive performance is needed to confirm this
hypothesis.
Some limitations in our study need to be addressed. First, we
could not draw a solid conclusion from these imaging data,
because this study is not based on pathological data. Second, the
relatively small sample size may have limited the detection of
group differences. Third, the dosage of 80 mg/day of propranolol
may be suboptimal in some cases to declare inefficacy in response.
However, previous studies reported that most Asian cases with
response showed the efficacy at this dose which may be
subtherapeutic in Westerns [59,60]. Fourth, the idea that the
connection between OFC and LC may be involved in the
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pathogenesis of ET has not been well established yet. Further
investigations would be needed to support this hypothesis.
Taken together, the results of the present study suggest that the
presence of propranolol responsiveness may be a predictive factor
in determining ET subtypes in terms of neuroanatomical
heterogeneity. Further large studies with pathological data are
required to draw definite conclusions.
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